KHF 2024 ACRYL Booth/Photo=ACRYL
AI specialist ACRYL announced on the 11th that it participated in the 'International Hospital and Health Tech Fair (KHF 2024)' held at COEX in Samseong-dong, Seoul and unveiled a solution for assisting diagnosis of depression and prostate hyperplasia using AI.
KHF 2024 is the largest healthcare event that looks into the future of the medical field, and ACRYL demonstrated Estherf Deprex, a depression prediction solution, and Esther Prostex1, a prostate hyperplasia diagnosis assistance solution, at the event. Visitors were able to experience the solution and directly check the diagnosis process.
Esther Deprex (Depression Diagnosis Assistance) is a level 2 diagnostic assistance device that distinguishes between patients with depression and patients with other mental illnesses, and is an AI-based psychological assessment software. It analyzes the patient's emotions and mental state to support objective and efficient diagnosis. It converts interview records between medical staff and patients into data and extracts emotions using an AI algorithm to calculate the probability of depression.
Esther Prostex1 (Differential Diagnosis of Prostate Hyperplasia) is an AI technology-based software that can replace existing invasive tests by analyzing the cause of lower urinary tract symptoms of prostate hyperplasia. It is expected to have a cost-saving effect for invasive tests by learning from general test results.
ACRYL CEO Jin Park said, “ACRYL is leading the medical IT innovation that helps diagnose major diseases quickly and accurately based on AI technology through the disease prediction solution presented at this KHF 2024,” and “We will strive to accelerate the digital transformation of the healthcare industry through global commercialization in 2025.”
Source: Global Economic Daily (https://www.getnews.co.kr)